Evidence map›Paper›PMID 41946825›Full record

ArticleDrug delivery and translational research2026

Oleyl-hyaluronate nanoparticles for enhanced peroral bioavailability of encapsulated Coenzyme Q10.

Martin Juhaščik, František Fiala, Dagmar Čožíková, Hana Vágnerová, Jaromír Kulhánek, Anna Kocurková, Matěj Šimek, Anna Stránská, Lukáš Kubala, František Ondreáš

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Immunological drivers of oxidative stress in glaucoma: implications for antioxidant therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Martin JuhaščikContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
František FialaContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
Dagmar ČožíkováContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
Hana VágnerováContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
Jaromír KulhánekContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
Anna KocurkováDepartment of Biophysics of the Immune System, Institute of Biophysics, Czech Academy of Sciences, Královopolská 135, 612 00, Brno, Czech Republic.
Matěj ŠimekContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
Anna StránskáContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic.
Lukáš KubalaDepartment of Biophysics of the Immune System, Institute of Biophysics, Czech Academy of Sciences, Královopolská 135, 612 00, Brno, Czech Republic.
František OndreášContipro a.s., Dolní Dobrouč 401, 561 02, Dolní Dobrouč, Czech Republic. frantisek.ondreas@contipro.com.

Funding

Ministry of Education, Youth and Sports of the Czech Republic CZ.02.01.01/00/23_021/0009529
6 · The paper itself

Abstract

Hyaluronic acid (HA) is a biocompatible, mucosal-interacting polysaccharide that offers unique advantages for oral drug delivery. Chemical modification with hydrophobic groups transforms HA into an amphiphilic polymer capable of self-assembly and encapsulation of poorly soluble compounds. In this work, we developed an oral delivery system based on oleyl-hyaluronate (O-HA) for coenzyme Q10 (CoQ10), a lipophilic antioxidant with limited solubility and low bioavailability. The coenzyme Q10-loaded oleyl-hyaluronate nanoparticles (O-HAQ10) were prepared using a multistep solvent evaporation method, achieving a high CoQ10 loading of up to 13.8 g/L and an encapsulation efficiency typically exceeding 90%. Crucially, this platform achieved an exceptionally high drug loading capacity, substantially minimizing the surfactant burden typically required to stabilize highly lipophilic payloads. The nanoparticles exhibited nanoscale dimensions (200-300 nm), as confirmed by dynamic light scattering (DLS) and scanning electron microscopy (SEM). Comprehensive in vitro evaluation confirmed robust cytocompatibility with the Caco-2 human intestinal epithelial cell line. Furthermore, studies on porcine intestine demonstrated significantly enhanced mucosal accumulation compared to commercial liposomal and oil-based formulations, even following simulated gastric exposure. In vivo pharmacokinetic evaluation in mice confirmed a 72% increase in systemic bioavailability relative to the clinical gold-standard oil-based control. These findings highlight the potential of hydrophobically modified HA as a highly efficient, versatile platform for the peroral delivery of poorly soluble bioactives.

Indexed as

BioavailabilityCoenzyme Q10Hyaluronic acidNanoparticlesOleyl-hyaluronatePeroral delivery

Identifiers

PMID41946825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.